Amit Joharapurkar

Employment

• Zydus Research Centre Senior General Manager

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (76)

• Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease
  Experimental Neurology 2025 DOI: 10.1016/j.expneurol.2025.115181
  +Save
• Age-related changes in hematological and biochemical profiles of Wistar rats
  Laboratory Animal Research 2024 DOI: 10.1186/s42826-024-00194-7
  +Save
• Prolyl hydroxylase inhibitor desidustat attenuates autoimmune hemolytic anemia in mice
  International Immunopharmacology 2024 DOI: 10.1016/j.intimp.2024.113029
  +Save
• Inhibition of alternative complement system and prolyl hydroxylase ameliorates anaemia of inflammation
  Inflammopharmacology 2024 DOI: 10.1007/s10787-024-01592-y
  +Save
• HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia
  Toxicology and Applied Pharmacology 2024 DOI: 10.1016/j.taap.2024.116832
  +Save
• Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia
  Frontiers in Nephrology 2024 DOI: 10.3389/fneph.2024.1459425
  +Save
• HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases
  Drug Research 2024 DOI: 10.1055/a-2347-9919
  +Save
• Apigenin-6-C-glucoside ameliorates MASLD in rodent models via selective agonism of adiponectin receptor 2
  European Journal of Pharmacology 2024 DOI: 10.1016/j.ejphar.2024.176800
  +Save
• The Perspective of Using Flow Cytometry for Unpuzzling Hypoxia-Inducible Factors Signalling
  Drug Research 2023 DOI: 10.1055/a-2248-9180
  +Save
• Uncovering Novel Therapeutic Targets for Parkinson’s Disease
  ACS Chemical Neuroscience 2023 DOI: 10.1021/acschemneuro.3c00084
  +Save